FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS


Date/App# patent app List of recent Antagonist-related patents
08/14/14
20140228565
 Thienopyrimidinone derivatives as mglur1 antagonists patent thumbnailThienopyrimidinone derivatives as mglur1 antagonists
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as parkinson's disease and alzheimer's disease.
08/14/14
20140228441
 Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications patent thumbnailNovel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications
The invention relates to compounds of formula (i), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (i).
08/14/14
20140228398
 Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease patent thumbnailCombinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease
The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in parkinson's disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.. .
08/14/14
20140228378
 N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists patent thumbnailN-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
The invention provides novel substituted cyclopropane carboxamide compounds according to formula (i), their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.. .
08/14/14
20140228377
 Methylpiperidine derivative patent thumbnailMethylpiperidine derivative
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .
08/14/14
20140228362
 Method of treatment or prophylaxis patent thumbnailMethod of treatment or prophylaxis
The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin ii receptor 2 (at2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects.
08/14/14
20140228353
 Compounds and methods of treating diabetes patent thumbnailCompounds and methods of treating diabetes
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2a.
08/14/14
20140228212
 Pesticidal compositions patent thumbnailPesticidal compositions
Combinations suitable for agricultural use can include (i) a nematode-antagonistic biocontrol agent and (ii) one or more agents selected, independently of each other, from any one of (a) to (h): (a) at least one fungicide; (b) at least one insecticide; (c) at least one synthetic nematicide; (d) bacterium of the genus bacillus; (e) harpin; (f) isoflavones; (g) plant growth regulators; and/or (h) plant activators.. .
08/14/14
20140227718
 G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same patent thumbnailG protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same
The invention relates generally to g protein coupled receptors and in particular to agonists and antagonists of g protein receptors and methods of using the same.. .
08/14/14
20140227278
 Antibodies to human signal peptide-containing proteins patent thumbnailAntibodies to human signal peptide-containing proteins
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
08/14/14
20140227266
Nogo receptor antagonists
Disclosed are immunogenic nogo receptor-1 polypeptides, nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are nogo receptor antagonist polynucleotides.
08/14/14
20140227262
Pd-1 antagonists and methods for treating infectious disease
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by binding to and blocking pd-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of pd-1 such as pd-l1, thereby preventing (in whole or in part) the ligand from binding to pd-1 to deliver an inhibitory signal.
08/14/14
20140227258
Humanized anti-cmet antagonists
The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.. .
08/14/14
20140227254
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of bmp9 and/or bmp10, ligands for alk1, may also be used to inhibit angiogenesis in vivo..
08/14/14
20140227252
Methods and monitoring of treatment with a dll4 antagonist
Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. .
08/07/14
20140221964
Systems and methods for local drug delivery to kidneys
Drug-delivery systems for local drug delivery to kidneys and associated systems and methods are disclosed herein. One aspect of the present technology is directed to drug-delivery systems that include a physiological sensor, an implantable medical device, and a control module configured to communicate with the physiological sensor and to control delivery of a drug in response to a physiological parameter measured by the physiological sensor.
08/07/14
20140221492
Deuterated 2-amino-3-hydroxypropanoic acid derivatives
This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an nmda glycine-site antagonist..
08/07/14
20140221428
Arylsulfonamide ccr3 antagonists
Provided herein are arylsulfonamides that are useful for modulating ccr3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a ccr3-mediated disorder, disease, or condition..
08/07/14
20140221420
Ccr5 antagonists for treating hiv
Compounds that modulate the ccr5 chemokine receptor, pharmaceutical compositions containing them, and uses therefor in the treatment of hiv and related diseases are described.. .
08/07/14
20140221415
Method of treating dyskinesia
Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately..
08/07/14
20140221410
Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
08/07/14
20140221381
Thienopyrimidine compounds and use thereof
Wherein r1 is a c1-4 alkyl; r2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a c1-4 alkyl and (4′) a c1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a c1-4 alkoxy-c1-4 alkyl, (3′) a mono-c1-4 alkyl-carbamoyl-c1-4 alkyl, (4′) a c1-4 alkoxy and (5′) a mono-c1-4 alkylcarbamoyl-c1-4 alkoxy, or the like; r3 is a c1-4 alkyl; r4 is a c1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.. .
08/07/14
20140221350
Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
08/07/14
20140221206
Herbicidal composition comprising polymeric microparticles containing a herbicide
The invention provides a herbicidal composition comprising a mixture of: (a) polymeric microparticles containing a first herbicide, wherein the first herbicide is a synthetic auxin herbicide (e.g. Dicamba, mcpa or 2,4-d) or an acetolactate synthase (als) inhibitor herbicide (e.g.
08/07/14
20140220154
Method of treating pathologic heterotopic ossification
What is described is a method of preventing or treating heterotopic ossification, vascular calcification, and pathologic mineralization, comprising administering an drug, wherein the drug is an antagonist of the hedgehog (hh) pathway. For example the antagonist consists of arsenic trioxide, sodium arsenite, phenylarsine, gant-58, gant-61, zerumbone vismodegib (gdc-0449, genentech), bevacizumab, gemcitabine, nab-paclitaxel, folfir, folfox, ro4929097, cixutumumab, cisplatin, etoposide, ldac, decitabine, daunorubicin, cytarabin, rosiglitazone, goserelin, leuprolide, capecitabine, fluorouracil, leucovorin, oxaliplatin, irinotecan, diclofenac, bms-833923 (xl139), ipi-926—infinity pharmaceuticals, inc., lde225, leq506—novartis pharmaceuticals, tak-441 millennium pharmaceuticals, inc., and pf-04449913—pfizer, alone or in combination therapy.
08/07/14
20140220146
Use of opioid antagonists for treating urinary retention
The invention pertains to the use of opiod antagonists for the treatment of urinary retention.. .
08/07/14
20140220030
Use of cgrp antagonist compounds for treatment of psoriasis
The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (cgrp) antagonistic effect. Methods are also disclosed for identifying compounds with cgrp antagonist activity which thereby are suitable candidate compounds for treating psoriasis..
08/07/14
20140220027
1d05 pcsk9 antagonists
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“pcsk9”) are disclosed. The disclosed antagonists are effective in the inhibition of pcsk9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with pcsk9 activity.
08/07/14
20140220022
Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease
The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of pthrp, its isoforms or pthrp signalling. The present invention is also directed to methods of inhibiting the pthrp1-173 isoform through antagonists thereof, including monoclonal antibodies and sirna directed there against.
08/07/14
20140220015
Combinations of modalities for the treatment of diabetes
A method of treating, preventing, or delaying the progression of type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a t-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic t-lymphocyte-associated antigen 4 (ctla4) molecule and a type 1 diabetes autoantigen.
08/07/14
20140220014
Levels of bcma protein expression on b cells and use in diagnostic methods
The present invention provides a method of measuring the levels of bcma in a biological sample, specifically upon the b cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as sle, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
08/07/14
20140220012
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
08/07/14
20140220001
Methods and monitoring of treatment with a dll4 antagonist
Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. .
07/31/14
20140213621
Method for treatment of chronic neuropathic pain
Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as d-cycloserine or a glyt-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, nsaids or cox-2 inhibitors.
07/31/14
20140213605
Methods for treating eye disorders using opioid receptor antagonists
The present invention discloses methods for treating eye disorders using opioid receptor antagonists. The methods include the step of administering an effective amount of a topically-administered opioid receptor antagonist in the absence of moxifloxacin.
07/31/14
20140213538
Lysophosphatidic acid receptor antagonists
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.. .
07/31/14
20140213509
Beta-hairpin peptidomimetics as cxc4 antagonists
β-hairpin peptidomimetics of the general formula cyclo(-tyr1-his2-xaa3-cys4-ser5-ala6-xaa7-xaa8-arg9-tyr10-cys11-tyr12-xaa13-xaa14-dpro15-pro16-), disulfide bond between cys4 and cys11, and pharmaceutically acceptable salts thereof, with xaa3, xaa7, xaa8, xaa13 and xaa14 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing hiv infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from cxcr4 receptor activity; or where immunological diseases are mediated or resulting from cxcr4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy..
07/31/14
20140213470
Methods for use with baff antagonists
Baff plays a central role in acquired immunity. The disclosure identifies baff responsive genes that are substantially upregulated by administration of baff and substantially downregulated by treatment with a baff antagonist.
07/31/14
20140212460
Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures.
07/31/14
20140212448
Klebsiella antigens
The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens.
07/31/14
20140212426
Toll-like receptor 3 antagonists
Toll like receptor 3 (tlr3) antibody antagonists, polynucleotides encoding tlr3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.. .
07/31/14
20140212420
Soluble tumor necrosis factor receptor treatment of medical disorders
The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of tnfα by administering a tnfα antagonist, such as recombinant tnfr:fc.. .
07/31/14
20140212412
Use of il-33 antagonists to treat fibrotic disease
Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of il-33 are disclosed.. .
07/24/14
20140206876
2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists
Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/24/14
20140206836
Novel n- and c-terminal substituted antagonistic analogs of gh-rh
There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.
07/24/14
20140206722
Methods of use of phenoxypropylamine compounds to treat depression
Disclosed herein are compositions and methods for treating depression using compositions comprising a compound of formula i. Disclosed herein are compositions and methods for treating depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-ht1a receptor, as well as 5-ht reuptake inhibitory activity.
07/24/14
20140205675
Horse feed dietary supplement composition derived from chia seed composition
A horse feed dietary supplement composition increases the energy and improves the health and coat of a horse and is formed as a partially defatted seed meal composition that may be supplemented to a horse feed. The composition includes a shelf stable, partially defatted supercritical co2 fluid solvent extracted whole grain flour that is derived from salvia hispanica l.
07/24/14
20140205608
Use of c-fms antagonists
The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (oa) and/or pain. In accordance with the present invention, an antagonist of c-fms is effective in the treatment of osteoarthritis and/or pain.
07/24/14
20140205606
Anti c-met antibodies
The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. .
07/24/14
20140205602
Antagonist anti-cd40 monoclonal antibodies and methods for their use
Compositions and methods of therapy for treating diseases mediated by stimulation of cd40 signaling on cd40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-cd40 antibody or antigen-binding fragment thereof to a patient in need thereof.
07/24/14
20140205600
Methods of promoting fat loss comprising administering an alk7 inhibitor
The invention relates to alk7 soluble receptors and their uses as antagonists of the function of certain ligands such as gdf-8 (myostatin) and gdf-11. The alk7 soluble receptor of the invention is useful as antagonists of gdf-8 and gdf-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases.
07/24/14
20140205596
Organic compounds
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer..
07/24/14
20140205595
Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells.
07/17/14
20140200244
Phenylethanolamine-based nmda receptor antagonists
Wherein one or more of r1, r2, r3, r4, r5, or the ring formed by the joining of r1 and r2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing nmda receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the glun1/glun2b nmda receptor, particularly at the interface between glun1 and glun2b subunits.
07/17/14
20140200240
Methods for determining patient response to anti-platelet aggregation therapy
Diagnostic methods for determining whether an individual will benefit from a particular anti-thrombotic therapeutic agent are disclosed. The methods involve obtaining a biological sample that comprises platelets, from a patient who has been pre-administered a particular therapeutic agent, which is an antagonist of a receptor associated with the biochemical pathways involved in platelet aggregation, and exposing the platelets to an agonist of the receptor.
07/17/14
20140200236
Opioid agonist/antagonist combinations
The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome)..
07/17/14
20140200224
Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
The invention formula r1 is selected from the group consisting of hydrogen, linear c1-c3 alkyl and fluorinated linear c1-c3 alkyl; r2 is hydrogen or methyl; r is selected from the group consisting of hydrogen, halogen, c1-c2-alkyl, fluorinated c1-c2-alkyl, c1-c2-alkoxy and fluorinated c1-c2-alkoxy, r4 is c1-c2-alkyl or fluorinated c1-c2-alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the n-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula i and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine d3 receptor antagonists or dopamine d3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula i to a subject in need thereof..
07/17/14
20140200215
Lysophosphatidic acid receptor antagonists
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.. .
07/17/14
20140200200
Antagonists of cb1 receptor
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
07/17/14
20140199399
Use of tgf-beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a tgf-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the tgf-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother..
07/17/14
20140199376
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed..
07/17/14
20140199366
Sustained release intraocular implants and methods for treating ocular neuropathies
Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
07/17/14
20140199322
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
07/17/14
20140199315
Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
07/17/14
20140199299
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target cd3 on t cells and neutralize one or more biological activities of interleukin-6 (il-6), such as cd3 modulators including anti-cd3 antibodies and anti-il-6 antagonists including anti-il-6 antibodies, anti-il-6r antagonists including anti-il-6r antibodies, and/or anti-il-6/il-6r complex antagonists including anti-il-6/il-6r binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.. .
07/17/14
20140199237
Methods and compositions for modulation of olfml3 mediated angiogenesis
The present invention relates to antibodies against specific domains of olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the olfml3 antagonists..


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.538

3336

3 - 0 - 71